Search results for: 'complex needs'

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulatio...

The Transformational Health team at Frost & Sullivan provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry. The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recen...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...